BFN Biofusion

    
  Biofusion PLC
  24 June 2008
   

 For immediate release  24 June 2008

    BIOFUSION PLC
    ("Biofusion", "the Company" or "the Group")

    PRESENTATION AT THE THIRD ANNUAL Piper Jaffray 
    Europe Conference 

    Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class research into business, announces that
David Baynes, the Company's Chief Executive Officer, will be presenting at the Third Annual Piper Jaffray Europe Conference.  
    The conference will be held on Tuesday 24th and Wednesday 25th June 2008 at the ANdAZ Hotel, London EC2. David Baynes will give a
Corporate Presentation on Wednesday 25th June 2008 at 12:00 BST.  
    Simultaneous to the conference, there will be a live audio web cast of the Biofusion presentation. To connect to the web cast facility,
please go to http://www.piperjaffray.com/conferences approximately 5 minutes (11:55 BST) before the start of the presentation.
    For further information please contact:
 Biofusion                                             +44 (0)114 275 5555
 David Baynes, CEO
 Buchanan Communications                               +44 (0)20 7466 5000
 Mary-Jane Johnson / Lisa Baderoon / Catherine Breen 
 Nomura Code Securities                                +44 (0)20 7776 1200
 Phil Walker, Clare Terlouw

    About Biofusion plc
    Biofusion was established in 2002 to commercialise university-generated IP. Biofusion has signed long-term agreements with two of the
UK's top ten research intensive universities (University of Sheffield and Cardiff University) giving a combined R&D spend attributable to
Biofusion of approximately �114 million a year.
    Biofusion's first agreement was a ten-year exclusive arrangement with the University of Sheffield for the commercialisation of IP owned
by the University in the area of medical life sciences. Biofusion has shareholdings in a portfolio of Sheffield University spin-out
companies including Asterion, Axordia, Biohydrogen, Lifestyle Choices, Diurnal and Phase Focus. The University of Sheffield was ranked 5th
in the UK for the quality of its life sciences research and will be spending an estimated �0.5bn of research funding over the lifetime over
the life of the Sheffield Agreement.
    In January 2007, Biofusion completed a long-term exclusive agreement with Cardiff University, to commercialise 100% of all Cardiff
University's research-generated IP. Biofusion has shareholdings in a portfolio of Cardiff University spin-out companies including Abcellute,
Q-Chip and Morvus. Cardiff University was ranked 7th in the UK in the most recent research rankings and will be spending more than �1.0bn of
research funding over the lifetime over the life of the Cardiff Agreement.
    In September 2007 Biofusion signed a Memorandum of Understanding with Finance Wales, the provider of commercial funding to Wales-based
SMEs, detailing a co-investment strategy for investing in opportunities arising from Biofusion's exclusive IP pipeline agreement with
Cardiff University. Finance Wales already manages funds of more than �130m and has to date invested approximately �85m in Wales. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
NRAEAKKDALDPEFE

Biofusion (LSE:BFN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Biofusion (LSE:BFN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024